<?xml version="1.0" encoding="UTF-8"?>
<p id="p0280">We have isolated a herpes simplex virus resistant to acyclovir, phosphonoacetic acid, and foscarnet, a varicella-zoster virus resistant to acyclovir, penciclovir, foscarnet, and vidarabine, and a cytomegalovirus resistant to ganciclovir, foscarnet, and mizoribine by culturing the virus in the presence of these antiviral agents (
 <xref rid="bb0260" ref-type="bibr">Ida et al., 1999</xref>; 
 <xref rid="bb0255" ref-type="bibr">Ida et al., 2000</xref>; 
 <xref rid="bb0290" ref-type="bibr">Kamiyama, Kurokawa, &amp; Shiraki, 2001</xref>; 
 <xref rid="bb0315" ref-type="bibr">Kuramoto et al., 2010</xref>; 
 <xref rid="bb0355" ref-type="bibr">Kurosaki et al., 2004</xref>; 
 <xref rid="bb0405" ref-type="bibr">Miwa et al., 2005</xref>; 
 <xref rid="bb0410" ref-type="bibr">Mori et al., 1988</xref>; 
 <xref rid="bb0525" ref-type="bibr">Shiraki et al., 1983</xref>, 
 <xref rid="bb0530" ref-type="bibr">Shiraki et al., 1985</xref>). These resistant viruses replace the virus population in the presence of drug in vitro and in patients. The emergence and replacement of resistant strains occurs in the herpetic lesions in immunocompromised individuals when a lesion with viral growth is treated for at least one or two weeks.
</p>
